ArticleJournal of nanobiotechnology2015
Reduced graphene oxide induces transient blood-brain barrier opening: an in vivo study.
Article in Journal of nanobiotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 104 citations in OpenAlex.
- Structure-Biomedical Activity Relationship of Tunable Ceria-Graphene Nanocomposites Leading to Divergent Cellular Responses.International journal of molecular sciences · 2026Article
- Graphene Triggers Inflammation in Murine Microglia via Phagocytosis.Small science · 2026Article
- Detection of Metal-Containing Particles in FDA-Authorized and New Disposable Electronic Cigarette Aerosols.Environmental science & technology · 2025Article
- Assessment of neurobehavioral and histopathological impacts of graphene quantum Dots in NMRI mice.Scientific reports · 2025Article
- Application of the Tier 3 NIOSH occupational exposure banding process for the graphene family of nanomaterials: A case study.Journal of occupational and environmental hygiene · 2025Article
- Graphene Oxide, a Prominent Nanocarrier to Reduce the Toxicity of Alzheimer's Proteins: A Revolution in Treatment.Recent patents on nanotechnology · 2025Review
- Radiosensitizing properties of dual-functionalized carbon nanostructures loaded with temozolomide.Beilstein journal of nanotechnology · 2025Article
- Recent advances in two-dimensional materials for the diagnosis and treatment of neurodegenerative diseases.Discover nano · 2024Review
- Utilizing reactive oxygen species-scavenging nanoparticles for targeting oxidative stress in the treatment of ischemic stroke: A review.Open medicine (Warsaw, Poland) · 2024Review
- Interactions of Graphene Oxide and Few-Layer Graphene with the Blood-Brain Barrier.Nano letters · 2023Article
- Synthesis and Functionalization of Graphene Materials for Biomedical Applications: Recent Advances, Challenges, and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- The mechanical, optical, and thermal properties of graphene influencing its pre-clinical use in treating neurological diseases.Frontiers in neuroscience · 2023Review
- Influence of GO-Antisense miRNA-21 on the Expression of Selected Cytokines at Glioblastoma Cell Lines.International journal of nanomedicine · 2023Article
- Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis.Therapeutic advances in medical oncology · 2023Review
- A Historical Review of Brain Drug Delivery.Pharmaceutics · 2022Review
- Graphene Oxide Thin Films with Drug Delivery Function.Nanomaterials (Basel, Switzerland) · 2022Review
- An Update on Graphene-Based Nanomaterials for Neural Growth and Central Nervous System Regeneration.International journal of molecular sciences · 2021Review
- Recent advances in the development of nanomedicines for the treatment of ischemic stroke.Bioactive materials · 2021Review
- Graphene-based nanomaterials for breast cancer treatment: promising therapeutic strategies.Journal of nanobiotechnology · 2021Review
- Behavioural alterations induced by chronic exposure to 10 nm silicon dioxide nanoparticles.IET nanobiotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe blood-brain barrier (BBB) is a complex physical and functional barrier protecting the central nervous system from physical and chemical insults. Nevertheless, it also constitutes a barrier against therapeutics for treating neurological disorders. In this context, nanomaterial-based therapy provides a potential alternative for overcoming this problem. Graphene family has attracted significant interest in nanomedicine because their unique physicochemical properties make them amenable to applications in drug/gene delivery and neural interface.
resultsIn this study, reduced graphene oxide (rGO) systemically-injected was found mainly located in the thalamus and hippocampus of rats. The entry of rGO involved a transitory decrease in the BBB paracellular tightness, as demonstrated at anatomical (Evans blue dye infusion), subcellular (transmission electron microscopy) and molecular (junctional protein expression) levels. Additionally, we examined the usefulness of matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) as a new imaging method for detecting the temporal distribution of nanomaterials throughout the brain.
conclusionsrGO was able to be detected and monitored in the brain over time provided by a novel application for MALDI-MSI and could be a useful tool for treating a variety of brain disorders that are normally unresponsive to conventional treatment because of BBB impermeability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.